ClinicalTrials.gov
ClinicalTrials.gov Menu

Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02834234
Recruitment Status : Completed
First Posted : July 15, 2016
Last Update Posted : July 26, 2016
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Brief Summary:
Peritoneal mesothelioma is a rare disease representing one third of all mesothelioma and nothing is known about molecular characteristics of this disease. As main cancers, genetic heterogeneity is probable. This genomic profiling associates Comparative Genomic Hybridization (CGH) array, BAP1 sequencing and gene expression in order to discover a biomarker that could be used in the treatment of this rare disease. Corresponding histopathological and immunohistochemical report as all clinical data are available. All data with be merged to underline a few genes of interest on which we will focus our next investigations. Depending of our preliminary results, BAP1 mutations are expected, as it was also described in pleural mesothelioma. Mutations in oncogenic drivers that could be targeted by specific therapy will be on particular interest in management of this rare disease with bad prognosis.

Condition or disease Intervention/treatment
Peritoneal Mesothelioma Genetic: comparative genomic analysis

Study Type : Observational
Actual Enrollment : 33 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays
Study Start Date : May 2013
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Mesothelioma

Group/Cohort Intervention/treatment
Peritoneal mesothelioma specimens

The group harbors only patients who received the diagnosis of peritoneal mesothelioma after surgery. All patients are included in this group.

The CGH arrays will be realized on frozen samples (for the comparative genomic analysis).

Genetic: comparative genomic analysis
DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation




Primary Outcome Measures :
  1. BAP1 mutations [ Time Frame: Day 0 ]
    CGH Array


Biospecimen Retention:   Samples With DNA
mesothelioma tumor specimen and normal tissue specimen


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with diagnosis of peritoneal mesothelioma
Criteria

Inclusion Criteria:

  • surgical biopsy od the peritoneal tumor with frozen samples
  • age > 18 years old

Exclusion Criteria:

  • absence of peritoneal mesothelioma
  • absence of frozen samples

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT02834234     History of Changes
Other Study ID Numbers: D50828
First Posted: July 15, 2016    Key Record Dates
Last Update Posted: July 26, 2016
Last Verified: July 2016

Keywords provided by Hospices Civils de Lyon:
mesothelioma
peritoneum
genomic
CGH arrays

Additional relevant MeSH terms:
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial